SecBot SecBot
PRESS-RELEASE ·Filed Apr 17, 2026

EVAX

Evaxion
BULLISH
Impact 7/10
Horizonweeks Processed7mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight ▲ Bullish

Traders should monitor for follow-up announcements post-AACR presentation, including potential partnership talks or research expansions. This proof-of-concept strengthens Evaxion’s platform narrative, which may re-rate the stock if commercial interest materializes.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.45
T+0 close · Apr 17, 2026 · via day close
Latest settled
−31.91%
T+60 · $3.03
Vs SPY
−38.05%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 17 $4.45entry
  2. T+1 · 7mo ago +0.90%α +1.09% · $4.49
  3. T+5 · 7mo ago −9.44%α −9.99% · $4.03
  4. T+20 · 6mo ago −7.42%α −12.79% · $4.12
  5. T+60 · 4mo ago −31.91%α −38.05% · $3.03
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion announced new data from a collaboration with Duke University showing its AI-Immunology™ platform can identify endogenous retrovirus (ERV)-derived antigens for use in personalized vaccines for glioblastoma, a deadly brain cancer with limited treatment options. The findings, to be presented at AACR 2026, demonstrate a novel antigen source that could improve vaccine efficacy in low mutational burden cancers.

Key Facts

  • AI-Immunology™ platform identified ERV-derived antigens in glioblastoma tumor samples, a novel target source absent in normal tissue.
  • Data shows feasibility of including both ERV antigens and neoantigens in personalized vaccines for most glioblastoma patients.
  • Immunologic responses to ERV antigens were experimentally confirmed, supporting clinical potential.
  • Results to be presented at AACR Annual Meeting on April 22, 2026, increasing scientific visibility.
  • Glioblastoma has low mutational burden and few neoantigens, making this new antigen source highly significant.

Financial Impact

Non-dilutive scientific validation with potential to increase partnership and licensing interest; no immediate revenue impact but enhances platform valuation.

market_sentimentpartnership_potentialplatform_valuation

Risk Factors

  • Clinical application remains preclinical; no guarantee of therapeutic success in humans.
  • High market expectations could lead to sell-off if AACR data underwhelms or lacks robustness.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3276449

Track record

50 reports on EVAX

Performance horizon

6 of 10 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026